Head-to-head evidence
LB-102 (methylated amisulpride) vs Lurasidone
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Schizophrenia
Shared mechanism: Dopamine D2/D3 receptor + 5-HT7 receptor · full Schizophrenia pipeline
LB-102 (methylated amisulpride)
Developed by LB Pharmaceuticals
NCT06179108 · Phase 2 · completed
The trial randomized 359 participants to LB-102 or matched placebo and maintained quadruple masking of participants, clinicians, investigators, and outcome assessors. The primary clinical symptom endpoint, change in PANSS total score at Week 4, was significantly better with LB-102 than placebo for all three doses (50, 75, and 100 mg).
Next expected readout: June 2027 · NCT07363577 (registry estimate)
Lurasidone
Marketed by Sumitomo Pharma
NCT00549718 · Phase 3 · completed
The study randomized approximately 500 participants to lurasidone 40, 80, or 120 mg or placebo and used quadruple masking of participants, clinicians, investigators, and outcome assessors. Its clinical primary endpoint, change in total PANSS score over 6 weeks, favored lurasidone overall versus placebo and was statistically significant (p<0.05).
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: LB-102 (methylated amisulpride)'s landscape · Lurasidone's landscape